

## Selected Transmembrane Receptors – Structures, Interactions and Binding Site Analysis.

Jagna Witek<sup>1,2</sup>, Krzysztof Rataj<sup>1,2</sup>, Stefan Mordalski<sup>1</sup>, Tomasz Kosciolek<sup>1</sup>,  
Andrzej J. Bojarski<sup>1</sup>

<sup>1</sup> Department of Medicinal Chemistry, Institute of Pharmacology,  
Polish Academy of Sciences, Smętna 12, Kraków, Poland

<sup>2</sup> Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University,  
Gronostajowa 7, Kraków, Poland  
e-mail: [jagna.witek@gmail.com](mailto:jagna.witek@gmail.com)

G-protein coupled receptors (GPCRs), sharing constitution of seven transmembrane helices piercing cell membrane, are largely expressed in mammalian organisms. They are involved in a wide variety of physiological processes, such as autonomic nervous system transmission, immunological response, behaviour and mood regulation.

A number of receptors belonging to GPCR family is present in neural tissue and is considered to be involved in learning and memorizing processes. They can be modulated by exogenous compounds, what makes them a common target in drug research. Acquiring information about protein's structure is a basic step to discover interactions involved in ligand binding, which is crucial in design of potential therapeutic compounds. Since structures of proteins with transmembrane domains cannot be easily determined, it is almost impossible to construct their 3D conformation using physical methods. This is why homology modelling is extremely helpful in determining structures of such proteins. Moreover, application of Structural Interaction Fingerprints (SIFts) and averaged SIFt profiles, enables fast and convenient binding site analysis. Such approach allows to determine residues involved in ligand-protein interaction, reveal its type giving insight into binding site properties.

[1] Deng Z., Chuaqui C., Singh J.: *J. Med. Chem.* **47** (2004), 337 -344.

[2] Mordalski S., Kosciolek T., Kristiansen K., Sylte I., Bojarski A. J.: *Bioorg. Med. Chem. Lett.* **21** (22) (2011), 6816-6819.

[3] Filmore D.: *Mod. Drug Discovery* **2004**, 24-28.

### Acknowledgments

This study is supported by project UDA-POIG.01.03.01-12-100/08-00 co-financed by European Union from the European Fund of Regional Development (EFRD); <http://www.prokog.pl>